These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 33420186)

  • 21. Tackling COVID-19: identification of potential main protease inhibitors via structural analysis, virtual screening, molecular docking and MM-PBSA calculations.
    Al-Shar'i NA
    J Biomol Struct Dyn; 2021 Oct; 39(17):6689-6704. PubMed ID: 32734828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening Malaria-box compounds to identify potential inhibitors against SARS-CoV-2 M
    Ahamad S; Kanipakam H; Birla S; Ali MS; Gupta D
    Eur J Pharmacol; 2021 Jan; 890():173664. PubMed ID: 33131721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Pyrazole Derivatives of Usnic Acid as Novel Inhibitor of SARS-CoV-2 Main Protease Through Virtual Screening Approaches.
    Roney M; Singh G; Huq AKMM; Forid MS; Ishak WMBW; Rullah K; Aluwi MFFM; Tajuddin SN
    Mol Biotechnol; 2024 Apr; 66(4):696-706. PubMed ID: 36752937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Putative SARS-CoV-2 M
    Mazzini S; Musso L; Dallavalle S; Artali R
    Molecules; 2020 Aug; 25(16):. PubMed ID: 32824454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An efficient eco-friendly, simple, and green synthesis of some new spiro-N-(4-sulfamoyl-phenyl)-1,3,4-thiadiazole-2-carboxamide derivatives as potential inhibitors of SARS-CoV-2 proteases: drug-likeness, pharmacophore, molecular docking, and DFT exploration.
    El-Saghier AM; Enaili SS; Abdou A; Kadry AM
    Mol Divers; 2024 Feb; 28(1):249-270. PubMed ID: 37946070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants.
    Muhammad I; Rahman N; Gul-E-Nayab ; Niaz S; Basharat Z; Rastrelli L; Jayanthi S; Efferth T; Khan H
    Comput Biol Med; 2021 Jun; 133():104362. PubMed ID: 33894500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Chandel V; Tripathi G; Nayar SA; Rathi B; Kumar A; Kumar D
    J Biomol Struct Dyn; 2022; 40(19):8850-8865. PubMed ID: 33939590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.
    Achilonu I; Iwuchukwu EA; Achilonu OJ; Fernandes MA; Sayed Y
    J Mol Graph Model; 2020 Dec; 101():107730. PubMed ID: 32920239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On the search for COVID-19 therapeutics: identification of potential SARS-CoV-2 main protease inhibitors by virtual screening, pharmacophore modeling and molecular dynamics.
    Hassan A; Arafa RK
    J Biomol Struct Dyn; 2022 Oct; 40(17):7815-7828. PubMed ID: 33749545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease.
    Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M
    J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study.
    Refaey RH; El-Ashrey MK; Nissan YM
    Virology; 2021 Feb; 554():48-54. PubMed ID: 33370597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
    Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
    Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
    Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
    Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developing a SARS-CoV-2 main protease binding prediction random forest model for drug repurposing for COVID-19 treatment.
    Liu J; Xu L; Guo W; Li Z; Khan MKH; Ge W; Patterson TA; Hong H
    Exp Biol Med (Maywood); 2023 Nov; 248(21):1927-1936. PubMed ID: 37997891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting two potential sites of SARS-CoV-2 main protease through computational drug repurposing.
    Prakash A; Borkotoky S; Dubey VK
    J Biomol Struct Dyn; 2023 Apr; 41(7):3014-3024. PubMed ID: 35266856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment.
    Elzupir AO
    Molecules; 2021 Dec; 26(24):. PubMed ID: 34946540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 M
    Bharadwaj S; Azhar EI; Kamal MA; Bajrai LH; Dubey A; Jha K; Yadava U; Kang SG; Dwivedi VD
    J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.